PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA

tomokokikuchi4
May 9
1 min read

PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced that on May 6, 2025, it received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for miR-3140-3p, a naturally occurring microRNA currently under clinical development by the company.

Recent Posts

See All

PURMX Therapeutics Initiates Phase I Clinical Trial of MIRX002, a Novel MicroRNA-Based Anticancer Drug, for Head and Neck Cancer

PURMX Therapeutics, Inc. (hereinafter referred to as “PURMX”) (Head Office: 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima...

Raised funds through a third-party allocation of new shares from Keio Innovation Initiative, Inc.

PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is...

PURMX Therapeutics Raised Funds through a Third-party Allotment of New Shares from Yokohama Capital

We are pleased to announce that PURMX Therapeutics, Inc. (headquartered in Hiroshima City, Japan; Hidetoshi Tahara, President & CEO;...

Comments